Cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has been used as targeted adjuvant chemotherapy of patients with CRC harboring wild-type KRAS, NRAS, BRAF, and PIK3CA genotypes. This evidence concerns the gene KRAS and colorectal carcinoma.